Sanford Applied Biosciences (SAB) is being awarded a sole-source contract to provide research and development services in support of a feasibility study for use of Transchromosomic Bovine derived polyvalent human immunoglobin (Tc pAb) as a therapeutic or prophylactic agent against Venezuelan equine encephalitis (VEE).
Naval Medical Research Center (NMRC) is leading the research effort. This acquisition pertains to a particular segment of the study wherein SAB research staff has the unique capability and expertise in performing the required tasks involving the preparation and execution of Transchromosomic Bovine (Tc BovineTM) vaccination and post-vaccination serum sampling.
The base period of performance will be for 24 months and has an estimated value of $933,042.00 and there will be a 24 month option period with an estimated value of $759,960.00. The total estimated value of the contract including all options is $1,692,138.00.
SAB has developed the world’s first large animal platform technology to produce fully human antibodies, both monoclonal and polyclonal, using the latest advances in gene engineering and transfer to produce new biopharmaceuticals that help fight disease. The antibodies generated in this unique system have been shown to have high diversity and high affinity compared to other genetically engineered animal systems.
The company, headquartered in Sioux Falls, South Dakota is a part of Sanford Health, the largest rural health organization in the United States.